Phase 3 Pancreatic Cancer Trial, Recruiting NCT06953999 Sponsor: Akeso Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 3 Pancreatic Cancer Trial, Recruiting

NCT06953999
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form agreeing to take part in the study.
  • You are between 18 and 75 years old (any gender).
  • You are generally well enough to carry out light activity and care for yourself, based on a standard health scale used in cancer care (confirm with trial site).
  • Doctors expect you to live for at least 3 more months.
  • You have been diagnosed with a specific type of pancreatic cancer (pancreatic ductal adenocarcinoma) that has spread to other parts of the body and cannot be removed by surgery, confirmed by a tissue or cell sample.
  • You have not yet received any systemic (whole-body) treatment, such as chemotherapy, for this spread of pancreatic cancer.
  • You have at least one area of cancer that can be measured on a scan, using standard medical guidelines.
  • Your liver, kidneys, and other organs are working well enough to take part in the study (confirm with trial site for specific requirements).

Who may not be able to join:

  • You have a different type of pancreatic cancer, or a mixed type, confirmed by a tissue or cell sample.
  • You have active cancer that has spread to your brain or spinal cord.
  • You have a known inherited change (mutation) in the BRCA1, BRCA2, or PALB2 genes.
  • You have a significant build-up of fluid around your lungs, heart, or in your abdomen that needs to be drained regularly.
  • You have been diagnosed with another type of cancer in the past 5 years.
  • You have a history of serious bleeding problems or blood-clotting disorders, or you have had a significant bleeding event within the past month.
  • You have previously received treatments that target blood vessel growth (anti-angiogenic therapy) or treatments that use the immune system to fight cancer (immunotherapy).
  • You have an active autoimmune disease (where the immune system attacks the body) that has required treatment within the past 2 years.
  • You are currently pregnant or breastfeeding.
  • You are already taking part in another clinical trial that involves a treatment or intervention (observational studies or follow-up phases may be acceptable — confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-18116403289

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Akeso
Registry
ClinicalTrials.gov
Start date
11 June 2025
Est. completion
14 May 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall response (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov